CardiALLO cell therapy - BioCardia

Drug Profile

CardiALLO cell therapy - BioCardia

Alternative Names: CardiALLO

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCardia
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Heart failure
  • Preclinical Myocardial infarction

Most Recent Events

  • 19 Sep 2017 Adverse events and efficacy data from the investigator-led phase II Trident trial in Myocardial infarction released by BioCardia
  • 07 Sep 2017 BioCardia has patent protection for CardiALLO® cell therapy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top